Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 6/20 | 0.41 |
| ▸ | ITK | Q08881 | 6/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 4/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921128 | 0.80 | MET (0.46) | METPRMT5WDR77BTKITK | |
| SCHEMBL14883424 | 0.77 | JAK2 (0.54) | METPRMT5WDR77BTKITK | |
| SCHEMBL1566306 | 0.77 | ITK (0.54) | METPRMT5WDR77BTKITK | |
| SCHEMBL25841381 | 0.77 | MET (0.43) | METPRMT5WDR77BTKITK | |
| SCHEMBL14041214 | 0.77 | MET (0.43) | METPRMT5WDR77BTKITK | |
| SCHEMBL24005850 | 0.77 | PRMT5 (0.42) | PRMT5WDR77BTKITKNTRK1 | |
| SCHEMBL25971496 | 0.77 | BRD4 (0.47) | NTRK1GSK3BKITMAP3K11CLK1 | |
| SCHEMBL1774189 | 0.77 | NTRK1 (0.38) | PRMT5WDR77NTRK1GSK3BKIT | |
| SCHEMBL1772956 | 0.77 | MAP3K11 (0.39) | NTRK1GSK3BKITMAP3K11CLK1 | |
| SCHEMBL10212537 | 0.77 | PRMT5 (0.45) | PRMT5WDR77NTRK1GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | MET 2464/4885PRMT5 1613/4885WDR77 3008/4885 |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MET 542/4885PRMT5 2445/4885WDR77 2667/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | MET 2464/4885PRMT5 1613/4885WDR77 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.